May 26, 2026 | Read online

Morning Briefing: (NASDAQ: GANX) Just Hit Our Radar

Any content you receive is for information purposes only. Always conduct your own research.

*Sponsored

Gain Therapeutics Inc. (NASDAQ: GANX) Lands At The Top Of Today’s Market Maven Insights Watchlist — Tuesday, May 26, 2026

Don’t miss the next breakout — get real-time alerts sent straight to your phone!

Full Coverage On (GANX) Starts Now

Pull Up (GANX) While It’s Still Early…

May 26, 2026

Morning Briefing: (NASDAQ: GANX) Just Hit Our Radar

Dear Reader,

Neurodegenerative disease research continues to attract growing attention across the biotech sector, and this morning, Gain Therapeutics Inc. (NASDAQ: GANX) has moved firmly onto our radar.

The clinical-stage biotechnology company is advancing GT-02287, an orally administered treatment candidate being developed for Parkinson’s disease, while also leveraging its proprietary Magellan™ platform to identify additional next-generation therapies targeting neurological disorders.

Another factor beginning to stand out is the company’s relatively small public float, with approx. under 42M shares currently listed as available to the public.

What appears to be drawing renewed interest is the steady flow of recent clinical and biomarker data, upcoming regulatory milestones expected later this year, and the company’s plans to initiate a Phase 2 study in 2026.

With Parkinson’s disease remaining one of the largest unmet needs in neurodegenerative medi-cine, (GANX) is beginning to emerge as a profile worth following closely heading deeper into 2026.

(GANX) stands out as a company worth watching closely this morning — Tuesday, May 26, 2026.

Recent Analyst Targets Suggest Significant Upside Potential From Current Levels

Recent third-party analyst coverage on Gain Therapeutics (NASDAQ: GANX) continues to reflect significant upside potential from recent levels.

According to MarketBeat, the current average 12-month analyst target on (GANX) is approx. $8.50. Based on recent levels around $1.78, that average target implies approximately 378% upside potential.

Additional analysts also reflect similar targets:

Benzinga currently lists a consensus analyst target of approx. $8.00, with a high target of $12.00. Based on recent levels near $1.78, implying approx. 574% upside potential.
Fintel currently reports an average one-year analyst target of $7.75, implying approx. 335% upside potential from recent levels.

A Closer Look At The Biotech Advancing A Next-Gen Parkinson’s Therapy

Gain Therapeutics (NASDAQ: GANX) is a clinical-stage biotechnology company focused on developing next-generation therapies for neurodegenerative diseases, including Parkinson’s disease. The company specializes in allosteric small molecule therapies designed to restore the function of misfolded proteins associated with neurological disorders.

The company’s lead dr-ug candidate, GT-02287, is currently being evaluated in a Phase 1b clinical trial for Parkinson’s disease with or without a GBA1 mutation. GT-02287 is an orally administered, brain-penetrant small molecule designed to restore the activity of glucocerebrosidase (GCase), an enzyme linked to Parkinson’s disease progression and neurodegeneration.

Preclinical and early clinical findings have shown encouraging signals involving motor function, biomarker improvements, neuroinflammation reduction, and target engagement. The company has also stated that GT-02287 may have additional future applications in Gaucher’s disease, dementia with Lewy bodies, and Alzheimer’s disease.

Beyond its lead program, (GANX) utilizes its proprietary Magellan™ platform, an AI and physics-based dr-ug discovery engine designed to identify novel allosteric binding sites and develop additional therapies targeting complex diseases.

Management has indicated that the company remains on track to pursue Phase 2 development of GT-02287 in 2026 as additional clinical and regulatory milestones continue approaching.

Inside The Multi-Bil-Dollar Race To Treat Parkinson’s Disease

The neurodegenerative disease market continues attracting significant attention as phar-mace-utical and biotech companies race to develop next-generation therapies for Parkinson’s disease, Alzheimer’s disease, and related neurological disorders.

According to Grand View Research, the global Parkinson’s disease treatment market was valued at approximately $6.7B and is projected to continue expanding as aging populations grow worldwide:

Precedence Research also estimates the global Parkinson’s therapeutics market could surpass $11B over the next decade:

A major reason the sector continues drawing attention is the lack of disease-modifying therapies currently available. Most approved treatments today are primarily designed to manage symptoms rather than slow disease progression itself.

Reuters recently highlighted how large phar-mace-utical companies and emerging biotech firms are aggressively increasing investment across the neurodegenerative disease space as demand for next-generation therapies accelerates globally:

Meanwhile, Parkinson’s disease prevalence continues rising rapidly. According to the Parkinson’s Foundation, nearly 1M people in the United States alone are currently living with Parkinson’s disease, with approximately 90,000 new cases diagnosed annually:

That combination of rising patient demand, limited treatment options, and continued phar-mace-utical investment is helping position the neurodegenerative disease sector as one of the most closely watched areas across biotechnology heading deeper into 2026.

Clinical Progress Continues Building Momentum Heading Into 2026

• Additional Phase 1b Clinical & Biomarker Data Released: The company presented new Phase 1b clinical and biomarker findings for GT-02287 at the AD/PD™ 2026 International Conference in Copenhagen. Management highlighted data involving CNS target engagement, neuroinflammation markers, and continued durability signals tied to Parkinson’s disease progression.

• FDA Regulatory Update Provided: (GANX) announced it had submitted additional preclinical data requested by the FDA in support of its IND application for a planned U.S. Phase 2 study. Management stated that the company remains on track to begin Phase 2 development during Q3 2026, pending FDA clearance.

• Phase 2 Trial Expected In 3Q 2026: According to the company’s May 2026 corporate update, FDA clearance of the IND submission is anticipated during Q2 2026, with Phase 2 clinical development expected to begin in the third quarter of 2026.

• Ongoing Extension Study Continues Advancing: The company also reported that 16 of 19 participants elected to continue into the ongoing nine-month extension portion of the Phase 1b study, with completion expected in September 2026.

• New dr-ug Discovery Programs Emerging: Beyond GT-02287, the company recently highlighted additional preclinical programs involving novel allosteric GCase modulators, including GT-04686, which management stated is being prepared for IND-enabling studies targeting Parkinson’s disease and other neurological disorders.

• Multiple Anticipated Potential Catalysts Ahead: Management currently expects additional regulatory updates, Phase 2 initiation progress, and further Phase 1b clinical data throughout the remainder of 2026.

7 Factors Putting (GANX) At The Top Of Our Watchlist For Today — Tuesday, May 26, 2026

Active Parkinson’s Disease Program: The company is advancing GT-02287, an orally administered therapy candidate targeting Parkinson’s disease.
Recent Biomarker Data: New clinical and biomarker findings recently highlighted signals tied to neuroinflammation and target engagement.
Phase 2 Trial Expected In 2026: Management remains on track to pursue Phase 2 development later this year pending regulatory clearance.
Growing Analyst Coverage: Recent third-party analyst targets currently range from approximately $7 to $12 per share, implying roughly 335% to 574% upside potential from recent levels.
Small Public Float: Approximately 41.3M shares are currently listed as available to the public, according to publicly available market data.
Proprietary AI Discovery Platform: The company’s Magellan™ platform is designed to identify additional therapies targeting neurological disease.
Multiple 2026 Potential Catalysts Ahead: Additional clinical updates, regulatory milestones, and development progress remain expected throughout the year.

Pull Up (GANX) While It’s Still Early…

Gain Therapeutics (NASDAQ: GANX) is beginning to attract increasing attention as multiple clinical and regulatory milestones continue moving closer into view. The company recently released additional Phase 1b biomarker and clinical findings tied to GT-02287, while also preparing for a planned Phase 2 study expected to begin later in 2026 pending FDA clearance.

Beyond its lead Parkinson’s disease program, the company’s proprietary Magellan™ platform provides additional exposure to future neurological dr-ug discovery programs targeting complex neurodegenerative disorders. Management has also continued advancing additional allosteric small molecule candidates across its broader pipeline.

When you combine multiple anticipated 2026 potential catalysts, growing analyst coverage implying approximately 335% to 574% upside potential from recent levels according to publicly available market data, and a relatively small public float of approximately 41.3M shares, (GANX) stands out as a biotechnology profile worth watching closely.

We have all eyes on (GANX) this morning — Tuesday, May 26, 2026.

Take a closer look at (GANX) while it’s still early.

And keep an eye on your inbox — our next update could arrive sooner than expected.

Sincerely,
Tate Remington
Chief Editor, Market Maven Insights

^{MarketMavenInsights.com}^{(“MarketMavenInsights” or “MMI”) is owned by Source Coastal Media LLC, a multi member limited liability company. Data is provided from third-party sources and MMI is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MMI brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors.}

^{Pursuant to an agreement between Source Coastal Media LLC and TD Media LLC, Source Coastal Media LLC has been hired for a period beginning on 05/26/2026 and ending on 05/26/2026 to publicly disseminate information about (GANX:US) via digital communications. Under this agreement, TD Media LLC has paid Source Coastal Media LLC seven thousand five hundred USD (“Funds”). These Funds were part of the fifty thousand USD funds that TD Media LLC received from a third party named JRZ Capital LLC who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.}

^{Neither Source Coastal Media LLC, TD Media LLC and their member own shares of (GANX:US).}

^{Please see important disclosure information here:}^{https://marketmaveninsights.com/disclosure/ganx-vOTQw/#details}